PND54 COST-OF-ILLNESS TRAJECTORIES AMONG NEWLY DIAGNOSED MS PATIENTS TREATED WITH INTERFERONS, GLATIRAMER ACETATE, OR NATALIZUMAB: HEALTHCARE, SICKNESS ABSENCE, AND DISABILITY PENSION COSTS IN SWEDEN